Street Calls of the Week
Investing.com - Brookline Capital Markets has reiterated its Buy rating and $1.60 price target on iBio, Inc. (NASDAQ:IBIO), currently trading at $0.82, following the company’s fiscal year 2025 financial results. The stock, with a market capitalization of $16.31 million, has seen a significant decline of 87% over the past six months, though analyst targets range from $1.60 to $6.00.
iBio remains on schedule to file an Investigational New Drug (IND) application for IBIO-600 in the first quarter of 2026, according to Brookline Capital Markets.
The firm noted that IBIO-610 continues to progress through non-human primate (NHP) studies, with data expected in the fourth quarter of 2025.
In late August, iBio raised $50 million through a public offering of pre-funded warrants and warrants, strengthening its financial position.
The company’s cash position as of June 30, combined with proceeds from the recent offering, is expected to provide funding through the first quarter of calendar year 2027.
In other recent news, iBio, Inc. has announced a $50 million public offering aimed at funding its preclinical research programs. This offering includes pre-funded warrants and Series G and H warrants, priced at $0.699 per unit. The company has also received a notice from Nasdaq for not meeting the minimum bid price requirement, with 180 days to regain compliance. Brookline Capital Markets has lowered its price target for iBio to $1.60 from $3.60, maintaining a Buy rating, reflecting the impact of the recent public offering on the company’s financial outlook.
Additionally, iBio’s stock saw a significant increase after revealing promising preclinical data for its amylin receptor agonist antibody, which showed a 60% reduction in acute food intake in a mouse model of obesity. This development is part of iBio’s collaboration with AstralBio, focusing on selective activation of the amylin receptor. The company’s recent activities highlight its ongoing efforts in antibody research and development. These developments are crucial for investors monitoring iBio’s progress in the biotech sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.